NZ600478A - Beta-carbolines for use in the treatment of hearing loss and vertigo - Google Patents

Beta-carbolines for use in the treatment of hearing loss and vertigo

Info

Publication number
NZ600478A
NZ600478A NZ600478A NZ60047810A NZ600478A NZ 600478 A NZ600478 A NZ 600478A NZ 600478 A NZ600478 A NZ 600478A NZ 60047810 A NZ60047810 A NZ 60047810A NZ 600478 A NZ600478 A NZ 600478A
Authority
NZ
New Zealand
Prior art keywords
carboline
vertigo
methyl
trauma
carbolines
Prior art date
Application number
NZ600478A
Other languages
English (en)
Inventor
Hans Rommelspacher
Original Assignee
Audiocure Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audiocure Pharma Gmbh filed Critical Audiocure Pharma Gmbh
Publication of NZ600478A publication Critical patent/NZ600478A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ600478A 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo NZ600478A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (1)

Publication Number Publication Date
NZ600478A true NZ600478A (en) 2013-10-25

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600478A NZ600478A (en) 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo

Country Status (17)

Country Link
US (1) US9107914B2 (https=)
EP (1) EP2519238B1 (https=)
JP (1) JP5627705B2 (https=)
KR (1) KR20120098855A (https=)
CN (1) CN102844029A (https=)
AU (1) AU2010338669A1 (https=)
BR (1) BR112012015967B1 (https=)
CA (1) CA2785233C (https=)
DE (1) DE112010005017A5 (https=)
IL (1) IL220661A (https=)
IN (1) IN2012DN05066A (https=)
MX (1) MX2012007678A (https=)
NZ (1) NZ600478A (https=)
RU (1) RU2012132429A (https=)
SG (1) SG181599A1 (https=)
WO (1) WO2011079841A1 (https=)
ZA (1) ZA201204476B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120863B (zh) * 2013-03-14 2021-06-04 奥斯特克有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
LT2970890T (lt) 2013-03-14 2020-07-10 The Brigham And Women`S Hospital, Inc. Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui
EP2853533A1 (de) 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
CA3109104A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Fluoro .beta.-carboline compounds
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
AU2019339352B2 (en) 2018-09-12 2025-05-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
EP3772515A1 (en) 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
HUP0302962A2 (hu) * 1998-06-12 2003-12-29 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
CA2785233A1 (en) 2011-06-07
IL220661A (en) 2016-03-31
SG181599A1 (en) 2012-07-30
AU2010338669A1 (en) 2012-06-21
ZA201204476B (en) 2014-01-29
US9107914B2 (en) 2015-08-18
JP2013515752A (ja) 2013-05-09
DE112010005017A5 (de) 2012-10-04
IL220661A0 (en) 2012-08-30
US20130028958A1 (en) 2013-01-31
JP5627705B2 (ja) 2014-11-19
RU2012132429A (ru) 2014-02-10
EP2519238B1 (de) 2014-08-13
EP2519238A1 (de) 2012-11-07
MX2012007678A (es) 2012-09-12
IN2012DN05066A (https=) 2015-10-09
BR112012015967B1 (pt) 2019-08-27
CA2785233C (en) 2018-10-09
WO2011079841A1 (de) 2011-07-07
BR112012015967A2 (pt) 2016-04-19
KR20120098855A (ko) 2012-09-05
CN102844029A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
NZ600478A (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
JO3032B1 (ar) مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
IL212113A (en) A device for the implantation of a drug for glaucoma treatment
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
UA115320C2 (uk) Інгібітори кінази
UA105781C2 (uk) Низькомолекулярне полісульфатоване похідне гіалуронової кислоти і лікарський засіб, який його містить
MY161095A (en) Indole compound and pharmaceutical use thereof
NZ602510A (en) Treatment of lupus nephritis using laquinimod
MX2011011109A (es) Formulaciones orales de bendamustina.
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2012000136A (es) Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ597030A (en) Method for treatment of diseases
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
MX2010010455A (es) Formas solidas de un compuesto fosfoindol anti-vih.
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod
MX356814B (es) Métodos y composiciones para neuroprotección.
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
WO2007035121A3 (en) Isoflavones for treating mucopolysaccharidoses
EP4494704A3 (en) Use of cyclic amide derivatives to treat sleep disorders
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.
RU2010135224A (ru) Способ хирургического лечения макулярного отека после факоэмульсификации катаракты
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2015 BY PAVIS EG

Effective date: 20141212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2016 BY PAVIS EG

Effective date: 20151210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2017 BY PAVIS EG

Effective date: 20161219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2018 BY PAVIS GMBH

Effective date: 20171215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2019 BY PAVIS GMBH

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2020 BY PAVIS GMBH

Effective date: 20191220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2021 BY PAVIS PAYMENTS GMBH

Effective date: 20201223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2022 BY PAVIS GMBH

Effective date: 20211216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2023 BY PAVIS PAYMENTS GMBH

Effective date: 20221221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20231214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2025 BY PAVIS PAYMENT GMBH

Effective date: 20241216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2026 BY PAVIS PAYMENTS GMBH

Effective date: 20251217